Search results
Showing 16 to 30 of 1226 results for nice quality standards or clinical guidelines
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
This guide describes the process NICE uses to develop NICE quality standards
Interim process and methods statement for bringing together NICE guidance (PMG47)
This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes
Show all sections
- Overview
- Introduction
- 1 Why we are bringing together NICE guidance
- 2 Process and methods for incorporating NICE technology appraisals into NICE guideline topic areas
- 3 Approach to further development of process and methods for bringing together NICE guidance
- 4 Updates to this interim process and methods statement
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
The NICE integrated topic prioritisation manual provides an overview of the process through which NICE will identify new topics and updates for prioritisation, and the decision-making framework that will be utilised by the NICE prioritisation board. This manual updates and replaces NICE health technology evaluation topic selection; the manual
Show all sections
- Overview
- 1 Our transformation
- 2 Types of topics the manual covers
- 3 Topics that are not usually considered by NICE
- 4 Summary of the NICE-wide topic prioritisation process
- 5 Identifying priorities for the health and care system
- 6 Identifying new topics and updates of existing guidance
- 7 Eligibility criteria for using the prioritisation framework and direct routing to guidance development
Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.